Why the study?
Does TAVR improve mortality risk compared to SAVR in patients at low surgical risk?
Does TAVR improve mortality risk compared to SAVR in patients at low surgical risk?
In patients at low surgical risk, SAVR should remain the treatment of choice over TAVR due to an association with increased mortality risk.
No takes yet. Share an insight, caveat, or question.
May support SAVR preference in low-risk patients; challenges TAVR expansion and leaves open confirmatory RCTs.
Witberg et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: